NEOG vs IDXX

For growth investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). IDEXX Laboratories, Inc. (IDXX) offers the better valuation at 44. 3x trailing P/E (39. 9x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Neogen Corporation is actually cheaper at 25.

7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +8. 6%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: IDXX returned +568. 9% versus NEOG's -49. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IDEXX Laboratories, Inc.

(IDXX) is the lower-risk stock at 1. 35β versus Neogen Corporation's 1. 83β — meaning NEOG is approximately 36% more volatile than IDXX relative to the S&P 500. On balance sheet safety, Neogen Corporation (NEOG) carries a lower debt/equity ratio of 44% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEXX Laboratories, Inc.

(IDXX) is pulling ahead at 10. 4% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc. grew EPS 22. 6% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 1. 1% for NEOG. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Neogen Corporation (NEOG) trades at 25.

7x forward P/E versus 39. 9x for IDEXX Laboratories, Inc. — 14. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDXX: 33. 5% to $773. 13.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+568. 9% 10Y return). Neogen Corporation (NEOG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDXX: +568. 9%, NEOG: -49. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.